NAD+: the longevity coenzyme grouped with peptide therapeutics (but not a peptide)

NAD+ is not a peptide. it is a dinucleotide coenzyme built from nicotinamide and adenine, joined through two ribose sugars and two phosphate groups. it is included on a peptide-education site because longevity and recovery practice consistently treats NAD+ and its precursors alongside peptide therapeutics in stacks, clinics, and marketing. honest framing matters: NAD+ is biology that peptide-curious readers will encounter, not a peptide drug.

what is NAD+?

NAD+ is one of the central electron carriers of cellular metabolism. every cell in the body uses it to move electrons through glycolysis, the citric acid cycle, and oxidative phosphorylation. it is also the obligatory cofactor for several enzyme families that have become central to longevity research, including the sirtuins (NAD+-dependent deacetylases), the PARPs (involved in DNA repair), and CD38 (an immune cell surface enzyme).

chemically, NAD+ is a dinucleotide: it has no amino acids and no peptide bonds, which is what disqualifies it from being a peptide in any technical sense. biologically, however, NAD+ sits at the intersection of energy production, stress response, and cellular ageing, which is why it has become a longevity touchstone. it is consumed and regenerated constantly, and a substantial body of preclinical work has documented that tissue NAD+ levels decline with age in multiple organs.

the two most widely studied oral NAD+ precursors are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). both are converted intracellularly into NAD+ through the salvage pathway. injectable and IV NAD+ formulations, used in wellness clinics, are a separate category from oral precursors and have their own regulatory and clinical considerations.

how does it work?

NAD+ functions in two broad modes. as a coenzyme in redox reactions it cycles between NAD+ and NADH, accepting and donating electrons. as a substrate for "NAD+-consuming enzymes" (sirtuins, PARPs, CD38, SARM1) it is cleaved during enzymatic reactions, which is what makes it consumable rather than purely catalytic.

in the redox role, NAD+ is the workhorse cofactor that lets cells extract chemical energy from food. this part of the biology is textbook biochemistry and not what the longevity discussion is usually about.

the longevity-relevant role is the second mode. sirtuins, especially SIRT1 and SIRT3, are NAD+-dependent deacetylases that regulate mitochondrial function, oxidative-stress responses, and transcriptional programmes implicated in ageing. PARP1 consumes NAD+ during DNA-damage response. CD38, particularly active in inflammatory cells, consumes NAD+ and is a major driver of the age-related decline in tissue NAD+ levels. the simplified longevity hypothesis is that as we age, NAD+ supply does not keep pace with NAD+ consumption, sirtuin and PARP activity become limited, and many downstream age-associated processes degrade. raising NAD+ via precursor supplementation is the intervention this hypothesis suggests [1].

what does the human evidence show?

the strongest human evidence is on oral NAD+ precursors. multiple RCTs of nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) consistently show that oral precursors raise blood NAD+ in healthy adults. translation to clinically meaningful outcomes (muscle function, insulin sensitivity, vascular endpoints) is mixed and far less mature than the biomarker data.

Martens and colleagues in Nature Communications in 2018 reported that chronic NR supplementation was well tolerated and elevated whole-blood NAD+ in healthy middle-aged and older adults over 6 weeks, with no serious adverse events attributed to NR [2]. Elhassan and colleagues in Cell Reports in 2019 used skeletal muscle biopsies in older men to show that NR not only raised the muscle NAD+ metabolome but also induced transcriptomic and anti-inflammatory signatures consistent with the proposed sirtuin-related mechanism [3].

on the NMN side, Yoshino and colleagues in Science in 2021 reported that 10 weeks of NMN improved muscle insulin sensitivity in prediabetic women, a clinically relevant biomarker improvement in a population at metabolic risk [4]. Liao and colleagues in the Journal of the International Society of Sports Nutrition in 2021 reported that NMN combined with exercise training enhanced measures of aerobic capacity in amateur runners [5]. these are positive but moderate-sized signals in modest sample sizes.

on the harder clinical endpoints, the picture is more mixed. McDermott and colleagues in Nature Communications in 2024 (the NICE trial of NR in peripheral artery disease) tested whether raising NAD+ would improve walking performance in PAD; the primary endpoint was not met in the prespecified intention-to-treat analysis [6]. Orr and colleagues in GeroScience in 2024 tested NR in older adults with mild cognitive impairment in an RCT and reported no significant cognitive benefit on the primary endpoint [7]. the honest summary is: NAD+ precursors reliably raise NAD+ in humans, the early metabolic and inflammatory biomarker signals are real, and the harder clinical endpoints have not consistently translated, which the literature continues to work through.

regulatory status

oral nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) live in the US dietary-supplement category, not the drug category. there is no FDA-approved NAD+ drug product for longevity, fatigue, recovery, or cognitive indications. injectable and IV NAD+ in wellness clinics is a compounded preparation and is not equivalent to an approved medication.

in the US, oral NR was self-affirmed GRAS as a food ingredient and is sold as a dietary supplement. NMN has had a more contested regulatory journey: the FDA announced in 2022 that NMN had been previously authorised for investigation as a new drug, which would in principle preclude it from being sold as a dietary supplement, although enforcement remains limited and the market is broadly active.

injectable and IV NAD+ are not approved drug products in any major jurisdiction for any of the longevity indications they are marketed for. clinic-administered IV NAD+ is a compounded service, with the FDA having previously flagged concerns about specific compounded NAD+ products and about claims of disease treatment that exceed what the evidence supports. the World Anti-Doping Agency does not specifically prohibit NAD+ or its precursors at the time of writing.

safety profile

oral NAD+ precursors at studied doses have been generally well tolerated in published trials. flushing, nausea, headache, and gastrointestinal effects have been reported. injectable and IV NAD+ have their own safety considerations, including infusion reactions and the compounded-product concerns raised by the FDA.

the safety dataset on oral NR is the most mature. Martens and colleagues reported no significant safety signal over 6 weeks at the doses studied [2]. subsequent trials of NR up to 12 weeks in older adults have not changed that picture, and a recent safety review of NMN trials concluded that the available human data show NMN to be safe in the studied doses and durations [1].

the gaps to teach honestly: long-term (years) safety data are limited for both NR and NMN; injectable and IV NAD+ have no equivalent RCT safety dataset; pre-existing-malignancy considerations have been raised theoretically because PARP and sirtuin activation can influence cell-survival pathways, although no clinical cancer signal has emerged in trials so far. the practical asymmetry is that the highest exposure (IV NAD+ in clinics) has the thinnest evidence base.

where it fits in peptide therapy

NAD+ sits adjacent to peptide therapy rather than inside it. it shares a marketing context with longevity peptides, especially the GH-axis tools and tissue-repair peptides, and it intersects biologically with mitochondrial peptides and exercise-mimetic pathways. it is most useful to teach as the metabolic background that sirtuin biology and longevity practice sit on top of.

the closest functional comparison is NMN, the immediate NAD+ precursor, which is also not a peptide and is reviewed on its own page. on the actual peptide side, the longevity-adjacent peptide most often discussed alongside NAD+ is epithalon, a tetrapeptide with telomere-related claims and a much thinner controlled human evidence base.

on the metabolic side, NAD+ biology intersects with AMPK and mTOR signalling and with the mitochondrial peptide MOTS-c (an exercise mimetic encoded in the mitochondrial genome). those overlaps are why NAD+ and MOTS-c often appear together in longevity stacks.

for the broader background, the free peptides and your body module covers the underlying biology of the axes most often combined with NAD+ in practice, and the FDA-approved peptides reference is the right place to calibrate expectations on what regulatory status NAD+, NMN, and NR actually have.